ATE396990T1 - Makrocyclische inhibitoren der beta-sekretase - Google Patents

Makrocyclische inhibitoren der beta-sekretase

Info

Publication number
ATE396990T1
ATE396990T1 AT05776414T AT05776414T ATE396990T1 AT E396990 T1 ATE396990 T1 AT E396990T1 AT 05776414 T AT05776414 T AT 05776414T AT 05776414 T AT05776414 T AT 05776414T AT E396990 T1 ATE396990 T1 AT E396990T1
Authority
AT
Austria
Prior art keywords
beta secretase
macrocyclic inhibitors
macrocyclic
inhibitors
secretase
Prior art date
Application number
AT05776414T
Other languages
English (en)
Inventor
Andrew Stamford
Ying Huang
Guoqing Li
Corey Strickland
Johannes Voigt
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of ATE396990T1 publication Critical patent/ATE396990T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AT05776414T 2004-07-28 2005-07-26 Makrocyclische inhibitoren der beta-sekretase ATE396990T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US59189904P 2004-07-28 2004-07-28

Publications (1)

Publication Number Publication Date
ATE396990T1 true ATE396990T1 (de) 2008-06-15

Family

ID=35106859

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05776414T ATE396990T1 (de) 2004-07-28 2005-07-26 Makrocyclische inhibitoren der beta-sekretase

Country Status (12)

Country Link
US (2) US7652003B2 (de)
EP (1) EP1781644B1 (de)
JP (1) JP2008508289A (de)
CN (1) CN101027297B (de)
AR (1) AR050184A1 (de)
AT (1) ATE396990T1 (de)
CA (1) CA2575340A1 (de)
DE (1) DE602005007245D1 (de)
ES (1) ES2306200T3 (de)
MX (1) MX2007001102A (de)
TW (1) TWI297337B (de)
WO (1) WO2006014944A1 (de)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
US7700603B2 (en) 2003-12-15 2010-04-20 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7763609B2 (en) * 2003-12-15 2010-07-27 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7592348B2 (en) 2003-12-15 2009-09-22 Schering Corporation Heterocyclic aspartyl protease inhibitors
GB0500683D0 (en) * 2005-01-13 2005-02-23 Novartis Ag Organic compounds
BRPI0606636A2 (pt) * 2005-01-13 2009-07-07 Novartis Ag compostos macrocìclicos úteis como inibidores de bace
SG162790A1 (en) 2005-06-14 2010-07-29 Schering Corp Aspartyl protease inhibitors
ATE482214T1 (de) 2005-06-14 2010-10-15 Schering Corp Aspartylproteasehemmer
KR20180058863A (ko) 2005-11-30 2018-06-01 애브비 인코포레이티드 아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도
PT1954718E (pt) 2005-11-30 2014-12-16 Abbvie Inc Anticorpos anti-globulómeros aβ, suas porções de ligação ao antigénio, correspondentes hibridomas, ácidos nucleicos, vectores, células hospedeiras, métodos de produção dos ditos anticorpos, composições compreendendo os ditos anticorpos, usos dos ditos anticorpos e métodos para uso dos ditos anticorpos
US8168641B2 (en) 2006-06-12 2012-05-01 Schering Corporation Aspartyl protease inhibitors
CA2656869A1 (en) * 2006-07-20 2008-01-24 Novartis Ag Macrocyclic lactams
JP2010505833A (ja) 2006-10-06 2010-02-25 メルク エンド カムパニー インコーポレーテッド アルツハイマー病を治療するためのマクロ環式スピロピペリジンβ−セクレターゼ阻害剤
JP5379692B2 (ja) 2006-11-09 2013-12-25 プロビオドルグ エージー 潰瘍、癌及び他の疾患の治療のためのグルタミニルシクラーゼの阻害薬としての３−ヒドロキシ−１，５−ジヒドロ−ピロール−２−オン誘導体
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
EP2091948B1 (de) 2006-11-30 2012-04-18 Probiodrug AG Neue inhibitoren von glutaminylcyclase
MX2009006228A (es) 2006-12-12 2009-06-22 Schering Corp Inhibidores de aspartil proteasa.
US20100311767A1 (en) 2007-02-27 2010-12-09 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
CA2679446C (en) 2007-03-01 2016-05-17 Probiodrug Ag New use of glutaminyl cyclase inhibitors
US9656991B2 (en) 2007-04-18 2017-05-23 Probiodrug Ag Inhibitors of glutaminyl cyclase
CN101848897A (zh) 2007-09-06 2010-09-29 先灵公司 γ分泌酶调节剂
WO2009061699A1 (en) 2007-11-05 2009-05-14 Schering Corporation Gamma secretase modulators
CA2708300A1 (en) 2007-12-11 2009-06-18 Schering Corporation Gamma secretase modulators
AU2009239536C1 (en) 2008-04-22 2012-12-13 Merck Sharp & Dohme Corp. Phenyl-substituted 2-imino-3-methyl pyrrolo pyrimidinone compounds as BACE-1 inhibitors, compositions, and their use
AU2009314049B2 (en) 2008-11-13 2015-03-05 Merck Sharp & Dohme Corp. Gamma secretase modulators
EP2379566A2 (de) 2008-12-22 2011-10-26 Schering Corporation Modulatoren von gamma-sekretase
JP2012513399A (ja) 2008-12-22 2012-06-14 シェーリング コーポレイション γ−セクレターゼ調節剤
WO2010147975A1 (en) 2009-06-16 2010-12-23 Schering Corporation Gamma secretase modulators
EP2443118A1 (de) 2009-06-16 2012-04-25 Schering Corporation Gammasekretasemodulatoren
WO2010147969A2 (en) 2009-06-16 2010-12-23 Schering Corporation Gamma secretase modulators
BR112012008346B1 (pt) 2009-09-11 2021-12-21 Vivoryon Therapeutics N.V. Derivados heterocíclicos, seu processo de preparação, e composição farmacêutica
EP2485591B1 (de) 2009-10-08 2016-03-23 Merck Sharp & Dohme Corp. Iminothiadiazindioxinverbindungen als bace-hemmer, zusammensetzungen und ihre verwendung
US8557826B2 (en) 2009-10-08 2013-10-15 Merck Sharp & Dohme Corp. Pentafluorosulfur imino heterocyclic compounds as BACE-1 inhibitors, compositions, and their use
UA108363C2 (uk) 2009-10-08 2015-04-27 Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування
EP2485920B1 (de) 2009-10-08 2016-04-27 Merck Sharp & Dohme Corp. Heterozyklische pentafluorsulfur-imin-verbindungen als bace-1-hemmer sowie zusammensetzungen damit und ihre verwendung
WO2011107530A2 (en) 2010-03-03 2011-09-09 Probiodrug Ag Novel inhibitors
DK2545047T3 (da) 2010-03-10 2014-07-28 Probiodrug Ag Heterocycliske inhibitorer af glutaminylcyclase (QC, EC 2.3.2.5)
MX336196B (es) 2010-04-15 2016-01-11 Abbvie Inc Proteinas de union a amiloide beta.
EP2560953B1 (de) 2010-04-21 2016-01-06 Probiodrug AG Hemmer der glutaminylzyklase
EP3533803B1 (de) 2010-08-14 2021-10-27 AbbVie Inc. Anti-amyloid-beta antikörper
WO2012123563A1 (en) 2011-03-16 2012-09-20 Probiodrug Ag Benz imidazole derivatives as inhibitors of glutaminyl cyclase
EP2694489B1 (de) 2011-04-07 2017-09-06 Merck Sharp & Dohme Corp. C5-c6-oxacyclus-fusionierte thiadiazindioxidverbindungen als bace-hemmer sowie zusammensetzungen daraus und ihre verwendung
US9181236B2 (en) 2011-08-22 2015-11-10 Merck Sharp & Dohme Corp. 2-spiro-substituted iminothiazines and their mono-and dioxides as bace inhibitors, compositions and their use
CN104270945B (zh) 2012-03-19 2017-03-29 巴克老龄化研究所 App特异性bace抑制剂(asbi)及其用途
WO2014056816A1 (en) 2012-10-10 2014-04-17 F. Hoffmann-La Roche Ag COMBINATION OF AN Aβ ANTIBODY AND A BACE INHIBITOR
EP2908824B1 (de) 2012-10-17 2018-05-02 Merck Sharp & Dohme Corp. Tricyclische substituierte thiadiazindioxidverbindungen als bace-hemmer, zusammensetzungen und deren verwendung
WO2014062549A1 (en) 2012-10-17 2014-04-24 Merck Sharp & Dohme Corp. Tricyclic substituted thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
CA2899938C (en) 2013-02-12 2021-10-19 Buck Institute For Research On Aging Hydantoins that modulate bace-mediated app processing
CN105175488A (zh) * 2015-09-07 2015-12-23 西北农林科技大学 一种具有抗老年痴呆症活性的化合物及其制备方法
JP7368856B2 (ja) 2017-07-25 2023-10-25 トゥルーバインディング，インコーポレイテッド Ｔｉｍ－３とそのリガンドとの相互作用の遮断によるがん治療
PL3461819T3 (pl) 2017-09-29 2020-11-30 Probiodrug Ag Inhibitory cyklazy glutaminylowej
CN120058944A (zh) 2019-01-30 2025-05-30 真和制药有限公司 抗gal3抗体及其用途
JP2023528797A (ja) 2020-05-26 2023-07-06 トゥルーバインディング，インコーポレイテッド ガレクチン－３を遮断することにより炎症性疾患を処置する方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989003842A1 (en) 1987-10-21 1989-05-05 The Upjohn Company Renin inhibitors containing a (1-amino-2-hydroxy-2-heterocyclic) ethyl moiety
DE60116313T2 (de) 2000-06-30 2006-08-31 Elan Pharmaceuticals, Inc., San Francisco Verbindungen zur behandlung der alzheimerischen krankheit
PE20020276A1 (es) 2000-06-30 2002-04-06 Elan Pharm Inc COMPUESTOS DE AMINA SUSTITUIDA COMO INHIBIDORES DE ß-SECRETASA PARA EL TRATAMIENTO DE ALZHEIMER
US6846813B2 (en) 2000-06-30 2005-01-25 Pharmacia & Upjohn Company Compounds to treat alzheimer's disease
WO2002088101A2 (en) 2001-04-27 2002-11-07 Vertex Pharmaceuticals Incorporated Inhibitors of bace
BR0210391A (pt) * 2001-06-12 2004-06-15 Elan Pharm Inc Composto, métodos de tratar um paciente que tenha ou de prevenir um paciente de contrair uma doença ou condição e de preparar um composto, e, uso de um composto
ATE323084T1 (de) * 2001-06-12 2006-04-15 Elan Pharm Inc Für die behandlung von alzheimer krankheit geeignete makrocyclen
US20040171614A1 (en) * 2002-02-06 2004-09-02 Schering-Plough Corporation Novel gamma secretase inhibitors
ATE443043T1 (de) * 2002-11-12 2009-10-15 Merck & Co Inc Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer
CA2512111A1 (en) * 2003-01-07 2004-07-29 Merck And Co., Inc. Macrocyclic beta-secretase inhibitors for treatment of alzheimer's disease
ATE444962T1 (de) * 2004-06-16 2009-10-15 Wyeth Corp Amino-5,5-diphenylimidazolon-derivate zur beta- sekretase-hemmung
JP2008503460A (ja) * 2004-06-16 2008-02-07 ワイス β−セクレターゼのインヒビターとしてのジフェニルイミダゾピリミジンおよびイミダゾールアミン
JP2009500329A (ja) 2005-06-30 2009-01-08 ワイス アミノ−５−（６員）ヘテロアリールイミダゾロン化合物およびβ−セレクターゼ調節のためのその使用
TW200738683A (en) 2005-06-30 2007-10-16 Wyeth Corp Amino-5-(5-membered)heteroarylimidazolone compounds and the use thereof for β-secretase modulation
TW200730523A (en) 2005-07-29 2007-08-16 Wyeth Corp Cycloalkyl amino-hydantoin compounds and use thereof for β-secretase modulation
AU2006294620A1 (en) 2005-09-26 2007-04-05 Wyeth Amino-5- [4- (difluoromethoxy) phenyl] -5-phenylimidazolone compounds as inhibitors of the beta-secretase (bace)
CN101460480A (zh) 2006-04-05 2009-06-17 阿斯利康(瑞典)有限公司 2-氨基嘧啶-4-酮类化合物及其用于治疗或预防Aβ相关病理的用途
TW200815447A (en) 2006-06-14 2008-04-01 Astrazeneca Ab Novel compounds IV
TW200815443A (en) 2006-06-14 2008-04-01 Astrazeneca Ab Novel compounds I
TW200808796A (en) 2006-06-14 2008-02-16 Astrazeneca Ab New compounds III
TW200815449A (en) 2006-06-14 2008-04-01 Astrazeneca Ab Novel compounds II
TW200815349A (en) 2006-06-22 2008-04-01 Astrazeneca Ab New compounds

Also Published As

Publication number Publication date
MX2007001102A (es) 2007-04-13
US20060040948A1 (en) 2006-02-23
ES2306200T3 (es) 2008-11-01
DE602005007245D1 (de) 2008-07-10
US20100178294A1 (en) 2010-07-15
TWI297337B (en) 2008-06-01
TW200607807A (en) 2006-03-01
AR050184A1 (es) 2006-10-04
CN101027297A (zh) 2007-08-29
US7652003B2 (en) 2010-01-26
JP2008508289A (ja) 2008-03-21
EP1781644B1 (de) 2008-05-28
HK1102328A1 (en) 2007-11-16
US8012953B2 (en) 2011-09-06
CA2575340A1 (en) 2006-02-09
CN101027297B (zh) 2010-09-08
EP1781644A1 (de) 2007-05-09
WO2006014944A1 (en) 2006-02-09

Similar Documents

Publication Publication Date Title
ATE396990T1 (de) Makrocyclische inhibitoren der beta-sekretase
CY2022001I2 (el) Παραγωγα του uk-2a
SI1891973T1 (sl) Kombinacije ki obsegajo antimuskarinska sredstvain PDE inhibitorje
CY2014012I2 (el) Χορηγηση αναστολεων διπεπτιδυλοπεπτιδασης
DK1802579T3 (da) Derivater af 3-arylaminopyridin
CR10815A (es) Nuevos derivados de isoquinolina e isoquinolinona sustituidos
ATE444962T1 (de) Amino-5,5-diphenylimidazolon-derivate zur beta- sekretase-hemmung
DE602005025733D1 (de) Pyrazolopyrimidinderivate als inhibitoren der cyclinabhängigen kinase
CY2013042I2 (el) Αναστολεις πυριδυλιου της σηματοδοτησης hedgehog
DK1888582T3 (da) Imidazo- og triazolopyridiner som hæmmere af 11-beta-hydroxysteroid dehydrigenase
DK1898903T3 (da) Inhibitorer af Akt-aktivitet
DK2049614T3 (da) Keramisk proppant med lav vægtfylde
DK1962830T3 (da) Azaindolhæmmere af aurorakinaser.
EP1873153A4 (de) Heterocyclische verbindung
ATE491693T1 (de) Substituierte amide als inhibitoren der beta- sekretase
ATE540936T1 (de) Substituierte 2-alkyl-chinazolinonderivate als parp-hemmer
EP1704145A4 (de) Selektive kinaseinhibitoren
ATE400271T1 (de) Aryl-pyridinderivate als 11-beta-hsd1-hemmer
EP1732566A4 (de) 6-azaindol-verbindung
DK1919907T5 (da) Heterocyklisk forbindelse
DOP2007000084A (es) Derivados de dihidropirazolopirimidinona
DK2097402T3 (da) Makrocykliske inhibitorer af hepatitis c-virus
ATE420076T1 (de) Indozolonderivate als 11b-hsd1-inhibitoren
IL189217A0 (en) Bridged n-bicylic sulfonamido inhibitors of gamma secretase
CR10879A (es) Cyclized derivatives as eg-5 inhibitors

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties